|
Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry. |
|
|
Speakers' Bureau - Celgene; Genentech; Millennium |
|
|
Consulting or Advisory Role - Algeta ASA; OptumRx; Seagen |
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst) |
Other Relationship - Celgene |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene |
Research Funding - Celgene |
|
|
Consulting or Advisory Role - Celgene |
Research Funding - Celgene |
|
|
Consulting or Advisory Role - Celgene |
|
|
Consulting or Advisory Role - Celgene; Genentech; Janssen Oncology; Medivation |
Research Funding - Celgene; Genentech; Medivation |
|
|
Research Funding - Celgene |
|
|
|
Consulting or Advisory Role - Celgene |
|
|
Consulting or Advisory Role - Celgene |
Research Funding - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Honoraria - Calistoga Pharmaceuticals; Pharmacyclics |
Consulting or Advisory Role - Celgene |
Research Funding - Celgene; Gilead Sciences; Pharmacyclics; Roche Pharma AG; TG Therapeutics |